<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056714</url>
  </required_header>
  <id_info>
    <org_study_id>PSI</org_study_id>
    <nct_id>NCT05056714</nct_id>
  </id_info>
  <brief_title>Development of a Severity Assessment Score for Nasosinus Polyposis (PSI Score)</brief_title>
  <acronym>PSI</acronym>
  <official_title>Development of a Severity Assessment Score for Nasosinus Polyposis (PSI Score)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      nasosinus polyposis (=PNS) is a chronic inflammatory disease of the nasal cavity and sinus&#xD;
      cavity with a prevalence of 2 to 4% in the general population. The functional impact of PNS&#xD;
      has a major impact on one's quality of life.Medical treatment, nasal irrigations and local&#xD;
      glucocorticoids as well as short treatment of oral glucocorticoids have shown a short-term&#xD;
      benefit versus placebo. Surgery improves the efficacy of local treatments, but 40% of&#xD;
      patients have a recurrence of polyps at 18 months and 20% of patients require a surgery&#xD;
      recovery at 5 years. The development of monoclonal antibodies directly targeting the&#xD;
      inflammatory way is a real public health issue. Bachert C. et al recently demonstrated the&#xD;
      efficacy of Dupilumab (anti-IL-4/13 antibody) injected subcutaneously on the overall&#xD;
      symptomatology of PNS. The marketing authorization (AMM) for the first biotherapy to be&#xD;
      available soon includes PNS's severe nature and resistance to treatment, although there is no&#xD;
      consensus definition or score to characterize this severity. This study aims at developping a&#xD;
      score for assessing severity in PNS. We suggest that this assessment strategy could be&#xD;
      applied to the PNS. The originality and the innovative character of this project is the&#xD;
      statistical modeling behind the creation of the score. Thus, the importance of symptoms,&#xD;
      anatomical and biological factors, the estimation of the quality of life of the patients, the&#xD;
      level of care use and the number of surgeries all become measurable indicators that are a&#xD;
      direct reflexion of the severity and the control of PNS, called latent variables because they&#xD;
      cannot be directly measured. To consider this detail, modeling using structural equations&#xD;
      seems optimal to develop a severity score (PSI score) of PNS in order to personalize the&#xD;
      therapeutic care of patients. Main Objective: To develop a severity score for PNS using&#xD;
      latent variable modeling: Polyps Severity Index (PSI)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In practice, during their otolaryngologist (ORL) consultation, patients will have a complete&#xD;
      clinical check-up and will be prescribed the necessary complementary examinations if they&#xD;
      have not already been performed recently (&lt;6 months). All data will be collected in an&#xD;
      anonymous database.&#xD;
&#xD;
      The patient will answer a questionnaire to evaluate the cardinal symptoms of PNS using a&#xD;
      visual scale from 0 to 10. He will then have a standard ORL clinical check-up (otoscopy, then&#xD;
      rhinoscopy with speculum and nasal endoscopy) in order to make a nasal anatomical assessment&#xD;
      (duration 5 minutes).&#xD;
&#xD;
      They will be given a questionnaire on admission to the waiting room to find out the impact of&#xD;
      their nasal discomfort on their quality of life (score used routinely and validated in the&#xD;
      literature, SNOT-22), as well as a questionnaire concerning their asthma if it exists (score&#xD;
      used routinely and validated in the literature, ACT). The importance of the endoscopic&#xD;
      involvement will be evaluated using the Lidholt score (see Appendix) and the importance of&#xD;
      the radiological involvement directly from the CT or Cone beam computed tomography (=CBCT)&#xD;
      results using the Lund-MacKay score. The estimated time to complete these questionnaires and&#xD;
      to assess the endoscopic and radiological involvement is an additional 10 minutes. Blood will&#xD;
      be drawn (as part of the initial routine workup) to assess complete blood count (for blood&#xD;
      hypereosinophilia) and IgE levels (serum and total IgE). We will repeat the assessment&#xD;
      routinely performed as part of the follow-up of patients with PNS by questionnaire, interview&#xD;
      and physical check-up at 3 months when the patients return for their follow-up visit. No&#xD;
      additional exams or questionnaires to the routine workup will be performed for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Develop a severity score for PNS using latent variable modeling: Polyps Severity Index (PSI)</measure>
    <time_frame>3 months</time_frame>
    <description>the estimated value of the structural coefficients relating measurable indicators of PNS to the endogenous latent variable: the severity of the disease (PSI score).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>patients with Nasosinus Polyposis</arm_group_label>
    <description>patients with Nasosinus Polyposis included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionaries</intervention_name>
    <description>The patient will answer several questionaries</description>
    <arm_group_label>patients with Nasosinus Polyposis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with nasosinisal polyposis identified or followed up&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years&#xD;
&#xD;
          -  Patients included are all adult (&gt;18 years) patients with PNS: Inflammation of the&#xD;
             nose and sinuses that is characterised by two or more of the following symptoms (at&#xD;
             least one of which must be nasal obstruction or runny nose):&#xD;
&#xD;
          -  Nasal obstruction and nasal congestion&#xD;
&#xD;
          -  Rhinorrhoea (anterior or posterior)&#xD;
&#xD;
          -  Facial pain or pressure&#xD;
&#xD;
          -  Decreased or loss of sense of smell&#xD;
&#xD;
          -  Sneezing and/or nasal pruritus&#xD;
&#xD;
        These symptoms should be associated with :&#xD;
&#xD;
          -  Endoscopic signs of nasal polyps&#xD;
&#xD;
          -  Diffuse bilateral naso-sinusal opacities on CT or CBCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decline to participate in the study&#xD;
&#xD;
          -  No one who speaks or understands French&#xD;
&#xD;
          -  History of skull base surgery for tumours&#xD;
&#xD;
          -  History of major head trauma&#xD;
&#xD;
          -  History of cerebral-facial radiotherapy or chemotherapy&#xD;
&#xD;
          -  History of inflammatory or neurodegenerative neurological pathology&#xD;
&#xD;
          -  Systemic disease associated with the presence of sinus polyps (Granulomatosis - with&#xD;
             polyangiitis, cystic fibrosis, primary ciliary dyskinesia, immune deficiency)&#xD;
&#xD;
          -  Cancer or haematological disease in progress&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilie BEQUIGNON</last_name>
    <phone>01 49 81 22 25</phone>
    <phone_ext>+33</phone_ext>
    <email>Emilie.bequignon@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille JUNG</last_name>
    <phone>01 45 17 50 00</phone>
    <phone_ext>+33</phone_ext>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>André COSTE</last_name>
      <phone>01 57 02 29 47</phone>
      <phone_ext>+33</phone_ext>
      <email>andre.coste@chicreteil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie BARTIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean François PAPON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Liile</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Geoffrey MORTUAIRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maxime FIEUX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Marseille Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Verillaud</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

